RCZY-843: A potential best-in-class, second-generation menin-MLL inhibitor engineered to overcome clinically observed menin-mutation-mediated resistance, with superior preclinical efficacy and safety in acute leukemia models

bleximenib (JNJ-6617) - J&J, Blackstone Health

Komzifti (ziftomenib) - Kura Oncology, Kyowa Kirin

RCZY-843 - Rongchang Pharmaceuticals

Revuforj (revumenib) - Syndax Pharma

Xiaojing (Celia) Chen1; Zhengyong Wan1; Xiaohong Liu1; Qiaoni You1; Shenjun Li2; Ling Wang2; Shanshan Bi2; Jing Jiang2; Jianming Bao1

Mar 18, 2026